Personal information

No personal information available

Activities

Collapse all

Employment (2)

Novartis Institutes for BioMedical Research Inc: Emeryville, CA, US

2017-06 to present | Director (Novartis Institute for Tropical Diseases (NITD))
Employment
Source: Self-asserted source
Ujjini Manjunatha

Novartis Institutes for BioMedical Research Inc: Singapore, Singapore, SG

2007-06 to 2017-06 | Senior Investigator at Drug Discovery Unit / Disease Biology Unit (Novartis Institute for Tropical Diseases (NITD))
Employment
Source: Self-asserted source
Ujjini Manjunatha

Education and qualifications (2)

National Institutes of Health: Bethesda, MD, US

2002 to 2007 | Post-doctoral Research Fellow (National Institute of Allergy and Infectious Diseases)
Qualification
Source: Self-asserted source
Ujjini Manjunatha

Indian Institute of Science: Bangalore, Karnataka, IN

1996 to 2002 | PhD (Microbiology and Molecular Biology)
Qualification
Source: Self-asserted source
Ujjini Manjunatha

Professional activities (1)

National University of Singapore: Singapore, SG

2009 to 2017 | Adjunct Asst. Professor (Dept of Microbiologym Yong Loo Lin School of Medicine )
Invited position
Source: Self-asserted source
Ujjini Manjunatha

Works (6)

Rapid-response RNA-fluorescence in situ hybridization (FISH) assay platform for coronavirus antiviral high-throughput screening

SLAS Discovery
2024-12 | Journal article
DOI: 10.1016/j.slasd.2024.100189
Contributors: Ryan Chan; Christian Shema Mugisha; Vorada Chuenchob; Stephanie A. Moquin; Ujjini H. Manjunatha; Nadine Jarrousse; Vineet D. Menachery; Xuping Xie; Erika L. Flannery; Richard T. Eastman
Source: check_circle
Crossref

Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent to treat paediatric enteric cryptosporidiosis

Nature Microbiology
2024-10-08 | Journal article
DOI: 10.1038/s41564-024-01810-x
Contributors: Ujjini H. Manjunatha; Suresh B. Lakshminarayana; Rajiv S. Jumani; Alexander T. Chao; Joseph M. Young; Jonathan E. Gable; Mark Knapp; Imad Hanna; Jean-Rene Galarneau; John Cantwell et al.
Source: check_circle
Crossref

Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science

Trends in Parasitology
2023-04 | Journal article
DOI: 10.1016/j.pt.2023.01.010
Contributors: Srinivasa P.S. Rao; Ujjini H. Manjunatha; Sebastian Mikolajczak; Paul G. Ashigbie; Thierry T. Diagana
Source: check_circle
Crossref

Use-case scenarios for an anti-Cryptosporidium therapeutic

PLOS Neglected Tropical Diseases
2021-03-11 | Journal article
DOI: 10.1371/journal.pntd.0009057
Contributors: Paul G. Ashigbie; Timothy G. Geary; Susan Shepherd; Kevin L. Steiner; Beatrice Amadi; Natasha Aziz; Ujjini H. Manjunatha; Jonathan M. Spector; Thierry T. Diagana; Paul Kelly
Source: check_circle
Crossref

Innovations in Addressing Pediatric Diarrhea in Low Resource Settings

ACS Infectious Diseases
2020-01-10 | Journal article
DOI: 10.1021/acsinfecdis.9b00315
Contributors: Rajiv S. Jumani; Jonathan M. Spector; Rasa Izadnegahdar; Paul Kelly; Thierry T. Diagana; Ujjini H. Manjunatha
Source: check_circle
Crossref

Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium

ACS Infectious Diseases
2018-04-13 | Journal article
DOI: 10.1021/acsinfecdis.7b00247
Contributors: Alexander T. Chao; Boon Heng Lee; Kah Fei Wan; Jeremy Selva; Bin Zou; Peter Gedeck; David John Beer; Thierry T. Diagana; Ghislain M. C. Bonamy; Ujjini H. Manjunatha
Source: check_circle
Crossref

Peer review (7 reviews for 3 publications/grants)

Review activity for ACS chemical biology. (1)
Review activity for ACS infectious diseases. (4)
Review activity for Nature communications (2)
How many people are using ORCID?